Ginkgo Bioworks Holdings, Inc. completed the divestiture of its Biosecurity business on April 3, 2026, receiving minority equity in the purchaser. Nine-month revenue fell to $67.3 million, while continuing-operations net loss narrowed to $174.4 million.
DNA · Ginkgo Bioworks Holdings, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Ginkgo won its first pharma autonomous lab sale with Novo Nordis in the third quarter of 2026. It held $285 million in cash and marketable securities, no bank debt, and reaffirmed cash burn guidance of 125 to 150 million dollars.
Ginkgo Bioworks signed its first autonomous lab sale to Novo and reported third quarter 2026 revenue of $28 million, a ($41) million GAAP net loss from continuing operations, ($22) million adjusted EBITDA, and $285 million in cash and marketable securities.
Ginkgo Bioworks will host a presentation and Q&A session on its third-quarter business performance on Thursday, November 5, 2026, beginning at 4:30 p.m. ET, reviewing the quarter ended September 30, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. Ginkgo reported declining revenue and remained loss-making, but improved its net loss and ended with $285 million of cash and no bank debt. Business momentum included a Novo autonomous lab sale, an ARPA-H subcontract worth up to $17.5 million, university commissions, and 22 ADME customers signed in Q3, although management did not guide revenue and system installations typically take six to 12 months.
- + Signed an autonomous lab sale to a top-tier pharma company, Novo. new
- + Won an ARPA-H subcontract worth up to $17.5 million for RNA-medicine manufacturing. new
- + Continued expansion through NSF-backed university commissions and MIT Media Lab's RAC-based cloud lab. new
- + Cloud Lab grew with 22 ADME customers signed in Q3, including 20 first-time Ginkgo customers. new
- + GAAP net loss from continuing operations improved to $41 million from $73 million year over year. new
- + Ended the quarter with $285 million in cash and no bank debt. new
- − Third-quarter revenue declined 6% year over year to $28 million.
- − Nine-month revenue declined 37% year over year to $67 million.
- − Adjusted EBITDA remained negative at $22 million, despite improving from negative $53 million. new
- − Adjusted EBITDA continued to absorb approximately $14 million of excess-lease carrying costs. new
- − Management did not provide revenue guidance or 2027 guidance. new
- − Autonomous lab sales typically face a six-to-12-month installation timeline. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -78.54M | Six Months Ended June 30, 2026 | — |
| EBITDA non-GAAP | -115.05M | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DNA
this stock
Ginkgo Bioworks Holdings, Inc.
|
$622.97M | +15.6% | -25.1% | — | 14.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 9, 2026
- This year
- 17
Ginkgo Bioworks Holdings, Inc. completed the divestiture of its Biosecurity business on April 3, 2026, receiving minority equity in the purchaser. Nine-month revenue fell to $67.3 million, while continuing-operations net loss narrowed to $174.4 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DNA | -14.9% | -6.4% | +10.6% | -14.3% | +15.6% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -17.5% | -5.3% | +10.1% | -14.1% | +5.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.